Sangamo Therapeutics (SGMOQ) Intangibles (2013 - 2023)

Sangamo Therapeutics has reported Intangibles for 8 years, with the latest figure at $51.6 million in Q1 2023.

• On a quarterly basis, Intangibles fell 2.13% year-over-year to $51.6 million in Q1 2023; TTM through Mar 2023 was $51.6 million, a 2.13% decrease from a year earlier, with the FY2022 full-year figure at $50.7 million, down 5.64% from the prior year.
• Intangibles was $51.6 million for Q1 2023 at Sangamo Therapeutics, up from $50.7 million in the prior quarter.
• The five-year high for Intangibles was $58.1 million in Q4 2020, with the low at $46.4 million in Q3 2022.
• Average Intangibles over 5 years is $53.1 million, with a median of $53.2 million recorded in 2019.
• The sharpest annual moves came in 2020 and 2022: Intangibles increased 9.35% in 2020, then decreased 15.45% in 2022.
• Over 5 years, Intangibles stood at $53.2 million in 2019, then gained by 9.35% to $58.1 million in 2020, then decreased by 7.51% to $53.8 million in 2021, then fell by 5.64% to $50.7 million in 2022, then advanced by 1.63% to $51.6 million in 2023.
• The last three Intangibles figures came in at $51.6 million (Q1 2023), $50.7 million (Q4 2022), and $46.4 million (Q3 2022), per Business Quant data.